In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast cancer than does conventional IHC-FISH pathology testing.

Makers of F-18 florbetapir (Amyvid) are bankrolling a lawsuit against the Centers for Medicare & Medicaid Services (CMS), which hampered coverage of amyloid imaging earlier this year as a means for ruling out Alzheimer’s disease. The lawsuit was filed in federal court by Lilly and others Sept. 5, according to this Wall Street Journal report.

A comparison study of three different methods of neuroendocrine tumor (NET) detection that includes PET/CT, SPECT/CT and whole body MR imaging places PET/CT with gallium-68 (Ga-68) DOTATATE on a pedestal above the rest for its sensitivity in finding NETs, according to a study published Aug. 28 in the Journal of Nuclear Medicine.

Schizophrenia may be tripped off by an overabundance of chemical signals pumped out by neurons in the brain. The University of California, San Diego, announced Sept. 11 that researchers from the Skaggs School of Pharmacy and Pharmaceutical Sciences are using stem cells to see the flood of neurotransmitters first-hand.

Ion Beam Applications (IBA) announced today that the company will be teaming up with Philips Healthcare to develop new diagnostic and therapeutic research and technology, including proton therapy systems.

Advanced Accelerator Applications (AAA) announced today that it has acquired GE Healthcare’s FDG-PET radiopharmaceutical division in Italy.

The American College of Radiology and the Medical Imaging and Technology Alliance are prompting all participants of the bone-imaging portion of the National Oncologic PET Registry (NOPR) to sign new agreements by Sept. 22.

While MRI is often considered one of the safer imaging modalities due to its lack of ionizing radiation, other dangers remain for patients, with thermal burns being a chief concern.